Bessemer Group
BIIB icon

Bessemer Group’s Biogen BIIB Stock Holding History

Bessemer Group’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$573K Buy
3,127
+416
+15% +$76.7K ﹤0.01% 1097
2025
Q4 		$478K Sell
2,711
-61
-2% -$9.97K ﹤0.01% 1146
2025
Q3 		$389K Sell
2,772
-772
-22% -$104K ﹤0.01% 936
2025
Q2 		$444K Buy
3,544
+507
+17% +$63.2K ﹤0.01% 857
2025
Q1 		$415K Buy
3,037
+729
+32% +$104K ﹤0.01% 921
2024
Q4 		$353K Sell
2,308
-384
-14% -$64.8K ﹤0.01% 969
2024
Q3 		$522K Sell
2,692
-639
-19% -$134K ﹤0.01% 884
2024
Q2 		$772K Buy
3,331
+277
+9% +$60.2K ﹤0.01% 719
2024
Q1 		$657K Buy
3,054
+43
+1% +$10.1K ﹤0.01% 751
2023
Q4 		$779K Sell
3,011
-2,055
-41% -$505K ﹤0.01% 713
2023
Q3 		$1.3M Sell
5,066
-333
-6% -$89.1K ﹤0.01% 559
2023
Q2 		$1.54M Buy
5,399
+1,064
+25% +$317K ﹤0.01% 541
2023
Q1 		$1.21M Sell
4,335
-55
-1% -$15.2K ﹤0.01% 555
2022
Q4 		$1.22M Sell
4,390
-170
-4% -$48K ﹤0.01% 544
2022
Q3 		$1.22M Buy
4,560
+883
+24% +$188K ﹤0.01% 545
2022
Q2 		$750K Sell
3,677
-10
-0.3% -$2.04K ﹤0.01% 620
2022
Q1 		$777K Buy
3,687
+854
+30% +$186K ﹤0.01% 529
2021
Q4 		$679K Buy
2,833
+695
+33% +$179K ﹤0.01% 549
2021
Q3 		$606K Sell
2,138
-273
-11% -$89.5K ﹤0.01% 524
2021
Q2 		$834K Buy
2,411
+259
+12% +$78.5K ﹤0.01% 452
2021
Q1 		$602K Sell
2,152
-1,844
-46% -$497K ﹤0.01% 502
2020
Q4 		$978K Sell
3,996
-887
-18% -$229K ﹤0.01% 404
2020
Q3 		$1.39M Sell
4,883
-3,030
-38% -$845K ﹤0.01% 363
2020
Q2 		$2.12M Buy
7,913
+4,081
+106% +$1.23M 0.01% 462
2020
Q1 		$1.21M Sell
3,832
-269
-7% -$81.6K ﹤0.01% 553
2019
Q4 		$1.22M Buy
4,101
+482
+13% +$134K ﹤0.01% 703
2019
Q3 		$843K Sell
3,619
-190
-5% -$44.2K ﹤0.01% 732
2019
Q2 		$891K Buy
3,809
+1,622
+74% +$375K ﹤0.01% 732
2019
Q1 		$518K Buy
2,187
+854
+64% +$269K ﹤0.01% 785
2018
Q4 		$401K Buy
1,333
+381
+40% +$122K ﹤0.01% 800
2018
Q3 		$336K Sell
952
-40
-4% -$13.8K ﹤0.01% 875
2018
Q2 		$288K Sell
992
-80
-7% -$22.5K ﹤0.01% 916
2018
Q1 		$293K Sell
1,072
-19
-2% -$5.9K ﹤0.01% 936
2017
Q4 		$347K Buy
1,091
+33
+3% +$10.6K ﹤0.01% 892
2017
Q3 		$331K Sell
1,058
-340
-24% -$101K ﹤0.01% 955
2017
Q2 		$379K Sell
1,398
-3,230
-70% -$854K ﹤0.01% 919
2017
Q1 		$1.26M Buy
4,628
+3,126
+208% +$884K 0.01% 638
2016
Q4 		$426K Buy
1,502
+555
+59% +$165K ﹤0.01% 921
2016
Q3 		$297K Sell
947
-1,181
-55% -$350K ﹤0.01% 900
2016
Q2 		$514K Buy
2,128
+348
+20% +$91.7K ﹤0.01% 546
2016
Q1 		$463K Sell
1,780
-7,817
-81% -$2.06M ﹤0.01% 570
2015
Q4 		$2.94M Buy
9,597
+415
+5% +$119K 0.02% 356
2015
Q3 		$2.68M Buy
9,182
+5,552
+153% +$1.83M 0.02% 362
2015
Q2 		$1.47M Buy
3,630
+194
+6% +$77.9K 0.01% 485
2015
Q1 		$1.45M Sell
3,436
-2,200
-39% -$867K 0.01% 464
2014
Q4 		$1.91M Buy
5,636
+2,961
+111% +$958K 0.01% 383
2014
Q3 		$885K Buy
2,675
+121
+5% +$39.9K 0.01% 480
2014
Q2 		$805K Buy
2,554
+232
+10% +$69.8K ﹤0.01% 489
2014
Q1 		$710K Buy
2,322
+105
+5% +$33.3K ﹤0.01% 485
2013
Q4 		$619K Sell
2,217
-3
-0.1% -$776 ﹤0.01% 511
2013
Q3 		$534K Sell
2,220
-531
-19% -$119K ﹤0.01% 530
2013
Q2 		$592K Buy
+2,751
New +$588K 0.01% 445

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bessemer Group's BIIB Position: Q1 2026 in Review

Bessemer Group increased its Biogen (BIIB) stake by 15% in Q1 2026, buying an estimated $76.7K and bringing the position to 3,127 shares worth $573K. The position accounts for ﹤0.01% of the portfolio, ranked #1097.

Bessemer Group first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.94M in Q4 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Bessemer Group held 3,127 shares of Biogen worth $573K as of Q1 2026.
  • Bessemer Group bought 416 Biogen shares in Q1 2026, an estimated $76.7K.
  • Biogen made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #1097 holding.
  • Bessemer Group first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
  • Bessemer Group's Biogen position peaked at $2.94M in Q4 2015.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.